Followers | 167 |
Posts | 36086 |
Boards Moderated | 7 |
Alias Born | 10/20/2019 |
![](https://investorshub.advfn.com/uicon/725019.png?cb=1611686644)
Thursday, November 02, 2023 10:23:01 AM
"Being able to substantially elevate NR2F6 levels is truly an unexpected, but welcome finding. We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple autoimmune disorders," says Dr. Harry Lander, Chief Scientific Consultant to the Company. "We recently filed a patent application around such T cells and we feel we have a head start on this in the scientific community, particularly around using nuclear receptors such as NR2F6."
$RGBP
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM